This activity is expired and is no longer available for CME credit.


Dr. Len Calabrese and Dr. Paul Sax Discuss the Current State of Herpes Zoster Vaccination - Prevention Strategies With a Focus on Immune-mediated Diseases

Author(s)/Faculty: Leonard H. Calabrese, DO; Paul E. Sax, MD
Release Date: 10/31/2020Expiration Date: 10/30/2021
Credit Type: CMENumber of Credits: 0
Content Type: PodcastProvider:
Shingles, also called herpes zoster (HZ), is a painful rash that develops due to reactivation of the varicella zoster virus, which causes chicken pox. Approximately 1 in 3 individuals in the United States will develop shingles during their lifetime, with adults over 50 years of age and immunocompromised individuals being at highest risk. Recent developments in HZ prevention include a new recombinant zoster vaccine, which is now recommended as the preferred shingles vaccine in updated guidelines from the Advisory Committee on Immunization Practices (ACIP). Effective prevention and risk management strategies are particularly important for patients with immune-mediated diseases. In this CME podcast, experts review vaccine safety and efficacy and discuss optimized use of vaccines for at-risk populations.